ITM Solucin GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Phase 1
Not yet recruiting
- Conditions
- NETLymphomaSolid Tumor, ChildhoodSomatostatin Receptor PositiveCNS Tumor
- Interventions
- Other: Amino Acid Solution
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT06441331
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Phase 3
Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRTDrug: CAPTEM (Capecitabine and Temozolomide)Other: Amino-Acid SolutionDrug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 250
- Registration Number
- NCT04919226
- Locations
- 🇪🇸
ICO Hospitalet, Catalan Institute of Oncology, Barcelona, Spain
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Affiliated Hospital of Jiangnan University, Wuxi, China
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
Phase 3
Active, not recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 309
- Registration Number
- NCT03049189
- Locations
- 🇦🇹
Allgemeines Krankenhaus Wien, Wien, Austria
🇵🇱"Gammed" Izabela Chuchrowksa, Warsaw, Poland
🇨ðŸ‡Inselspital, Universitätsspital Bern, Bern, Switzerland
© Copyright 2025. All Rights Reserved by MedPath